Medical devices, healthcare technology and the business of care
510(k) clearance · K254226

PulseAPI SmartWatch

PulseAI, Ltd. · Decision date Oct 27, 2026

MEDTECHLEDGER EXPLANATIONK254226

What did the FDA decide?

PulseAI, Ltd. received a substantially equivalent (SESE) decision for the PulseAPI SmartWatch under 510(k) K254226, dated October 27, 2026, with the FDA record listing a receipt date of December 29, 2025. The device is a Class II programmable diagnostic computer (21 CFR 870.1425, product code DQK) in the cardiovascular specialty. It is a software analysis library, not a standalone monitor, that receives ECG waveform data and metadata from lead I or lead II wet-electrode recordings or compatible dry-electrode devices and is meant to be integrated into other device software.

The submission names the AliveCor KardiaAI V2 (K201985) as predicate. The summary states the subject device has the same intended use and similar technological characteristics, with differences addressed through performance testing, including analyses using ANSI/AAMI EC57 reference datasets. SESE is a clearance, not a PMA approval. The indications exclude patients with pacemakers or other implanted electronic devices and exclude life-supporting or alarm-system use. The summary does not disclose quantitative performance results, so the basis for equivalence cannot be independently assessed from these documents.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Cardiovascular
Decision date
Oct 27, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K254226
Regulatory pathway
510(k) premarket notification
Applicant
PulseAI, Ltd.
Product code
DQK
Decision code
SESE
Decision date
Oct 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Computer, Diagnostic, Programmable.

Applicant
PulseAI, Ltd.
Product code
DQK
FDA device class
2

FDA decision timeline

  1. K254226 received

    Application receipt date recorded by FDA.

  2. K254226 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code DQK

Product / regulatory recordCompanyPathwayDecision dateSource
Merge Healthcare Incorporated510(k) clearanceNov 5, 2026FDA
Catheter Precision, Inc.510(k) clearanceOct 30, 2026FDA
Rhythm AI, Ltd.510(k) clearanceOct 23, 2026FDA
Centerline Biomedical510(k) clearanceOct 1, 2026FDA
Wellysis Corp.510(k) clearanceSep 25, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

PulseAI, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Belfast

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records